In this work, only patients scanned with F18‐FDG were included in the research protocol, and future work should investigate the performance of the CBM_DDG algorithm with radiotracers that are gaining more widespread use clinically such as Ga‐68 DOTATATE for neuroendocrine studies and F18‐Fluciclovine or PSMA labeled agents for prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.